Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis

被引:5
作者
Shen, Jiacheng [1 ]
Liu, Tingwei [1 ]
Bei, Qiaoli [1 ]
Xu, Shaohua [1 ]
机构
[1] Tongji Univ, Dept Gynecol, Shanghai Matern & Infant Hosp 1, Sch Life Sci & Technol, Shanghai, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
ovarian cancer; multi-omics; immune microenvironment; immune classification; immunotherapy; ANTITUMOR-ACTIVITY; IMMUNOTHERAPY; SAFETY; BREAST; CELLS;
D O I
10.3389/fonc.2021.685065
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian cancer has a low response rate to immunotherapy and a complex immune microenvironment that regulates its treatment outcomes. Understanding the immune microenvironment and its molecular basis is of great clinical significance in the effort to improve immunotherapy response and outcomes. To determine the characteristics of the immune microenvironment in ovarian cancer, we stratified ovarian cancer patients into three immune subtypes (C1, C2, and C3) using immune-related genes based on gene expression data from The Cancer Genome Atlas and found that these three subtypes had significant differences in immune characteristics and prognosis. Methylation and copy number variant analysis showed that the immune checkpoint genes that influenced immune response were significantly hypermethylated and highly deleted in the immunosuppressive C3 subtype, suggesting that epigenetic therapy may be able to reverse the efficacy of immunotherapy. In addition, the mutation frequencies of BRCA2 and CDK12 were significantly higher in the C2 subtype than in the other two subtypes, suggesting that mutation of DNA repair-related genes significantly affects the prognosis of ovarian cancer patients. Our study further elucidated the molecular characteristics of the immune microenvironment of ovarian cancer, which providing an effective hierarchical method for the immunotherapy of ovarian cancer patients, and has clinical relevance to the design of new immunotherapies and a reasonable combination strategies.
引用
收藏
页数:14
相关论文
共 49 条
[1]   Regulation of PD-L1 Expression by NF-κB in Cancer [J].
Antonangeli, Fabrizio ;
Natalini, Ambra ;
Garassino, Marina Chiara ;
Sica, Antonio ;
Santoni, Angela ;
Di Rosa, Francesca .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[2]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[3]   NF-κB and Its Role in Checkpoint Control [J].
Betzler, Annika C. ;
Theodoraki, Marie-Nicole ;
Schuler, Patrick J. ;
Doescher, Johannes ;
Laban, Simon ;
Hoffmann, Thomas K. ;
Brunner, Cornelia .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
[4]  
Billan S, 2020, LANCET ONCOL, V21, pE463, DOI 10.1016/S1470-2045(20)30328-4
[5]   Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer [J].
Bindea, Gabriela ;
Mlecnik, Bernhard ;
Tosolini, Marie ;
Kirilovsky, Amos ;
Waldner, Maximilian ;
Obenauf, Anna C. ;
Angell, Helen ;
Fredriksen, Tessa ;
Lafontaine, Lucie ;
Berger, Anne ;
Bruneval, Patrick ;
Fridman, Wolf Herman ;
Becker, Christoph ;
Pages, Franck ;
Speicher, Michael R. ;
Trajanoski, Zlatko ;
Galon, Jerome .
IMMUNITY, 2013, 39 (04) :782-795
[6]   Understanding the tumor immune microenvironment (TIME) for effective therapy [J].
Binnewies, Mikhail ;
Roberts, Edward W. ;
Kersten, Kelly ;
Chan, Vincent ;
Fearon, Douglas F. ;
Merad, Miriam ;
Coussens, Lisa M. ;
Gabrilovich, Dmitry I. ;
Ostrand-Rosenberg, Suzanne ;
Hedrick, Catherine C. ;
Vonderheide, Robert H. ;
Pittet, Mikael J. ;
Jain, Rakesh K. ;
Zou, Weiping ;
Howcroft, T. Kevin ;
Woodhouse, Elisa C. ;
Weinberg, Robert A. ;
Krummel, Matthew F. .
NATURE MEDICINE, 2018, 24 (05) :541-550
[7]   Immunotherapy for platinum-resistant ovarian cancer [J].
Bogani, Giorgio ;
Lopez, Salvatore ;
Mantiero, Mara ;
Ducceschi, Monika ;
Bosio, Sara ;
Ruisi, Simona ;
Sarpietro, Giuseppe ;
Guerrisi, Rocco ;
Brusadelli, Claudia ;
Dell'Acqua, Andrea ;
Di Donato, Violante ;
Raspagliesi, Francesco .
GYNECOLOGIC ONCOLOGY, 2020, 158 (02) :484-488
[8]   Can we predict who lives long with ovarian cancer? [J].
Bookman, Michael A. .
CANCER, 2019, 125 :4578-4581
[9]   Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma [J].
Dheilly, Elie ;
Battistello, Elena ;
Katanayeva, Natalya ;
Sungalee, Stephanie ;
Michaux, Justine ;
Duns, Gerben ;
Wehrle, Sarah ;
Sordet-Dessimoz, Jessica ;
Mina, Marco ;
Racle, Julien ;
Farinha, Pedro ;
Coukos, George ;
Gfeller, David ;
Mottok, Anja ;
Kridel, Robert ;
Correia, Bruno E. ;
Steidl, Christian ;
Bassani-Sternberg, Michal ;
Ciriello, Giovanni ;
Zoete, Vincent ;
Oricchio, Elisa .
CANCER CELL, 2020, 37 (05) :674-+
[10]   Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial [J].
Disis, Mary L. ;
Taylor, Matthew H. ;
Kelly, Karen ;
Beck, J. Thaddeus ;
Gordon, Michael ;
Moore, Kathleen M. ;
Patel, Manish R. ;
Chaves, Jorge ;
Park, Haeseong ;
Mita, Alain C. ;
Hamilton, Erika P. ;
Annunziata, Christina M. ;
Grote, Hans Juergen ;
von Heydebreck, Anja ;
Grewal, Jaspreet ;
Chand, Vikram ;
Gulley, James L. .
JAMA ONCOLOGY, 2019, 5 (03) :393-401